SANOFI PASTEUR
š«š·France
- Country
- š«š·France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of IMOVAX POLIOĀ® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan
Phase 4
Completed
- Conditions
- PoliomyelitisPolio
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 60
- Registration Number
- NCT02005536
Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.
Phase 3
Completed
- Conditions
- TetanusDiphtheriaPertussis
- Interventions
- Biological: DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)Biological: Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1440
- Registration Number
- NCT01993173
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
Phase 3
Completed
- Conditions
- DiphtheriaTetanusHaemophilus Influenzae Type bWhooping CoughHepatitis BPoliomyelitis
- Interventions
- Biological: Infanrix hexa + Prevenar + Rotarix vaccineBiological: DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccineBiological: DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 558
- Registration Number
- NCT01983540
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed
- Conditions
- Dengue Hemorrhagic FeverDengueDengue Fever
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3203
- Registration Number
- NCT01983553
Post-licensure Safety Study of IMOJEVĀ® in Thailand
Phase 4
Completed
- Conditions
- Japanese Encephalitis
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 10000
- Registration Number
- NCT01981967
Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Quadrivalent Influenza Vaccine (split virion, inactivated)
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 100
- Registration Number
- NCT01967784
A Study of Two Doses of Oral Cholera Vaccine (Shancholā¢) in Subjects Aged 1 Year and Older in the Philippines
Phase 4
Completed
- Conditions
- Cholera
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 336
- Registration Number
- NCT01949675
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
Phase 3
Completed
- Conditions
- Whooping CoughPoliomyelitisHepatitis BDiphtheriaTetanusInvasive Hib Infections
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 177
- Registration Number
- NCT01948193
Safety and Immunogenicity Among Healthy Children Receiving FluzoneĀ® Quadrivalent Influenza Virus Vaccine
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluzoneĀ® Quadrivalent Influenza Virus Vaccine, No Preservative
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 60
- Registration Number
- NCT01946425
Study of FluzoneĀ® Quadrivalent, FluzoneĀ® Intradermal, and FluzoneĀ® High-Dose Influenza Virus Vaccines in Adults
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluzoneĀ® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),Biological: FluzoneĀ® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),Biological: FluzoneĀ® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 208
- Registration Number
- NCT01946438
Ā© Copyright 2025. All Rights Reserved by MedPath